Respons Klinis Pemberian Tocilizumab Dibandingkan Anakinra dalam Tata Laksana Artritis Idiopatik Juvenil Sistemik

Edy Novery, Rizqi Amalia, Dina Muktiarti, Nia Kurniati

Sari


Latar belakang. Artritis idiopatik juvenil (AIJ) sistemik merupakan penyakit inflamasi sistemik yang tidak hanya melibatkan sendi tetapi juga keterlibatan sistemik dan merupakan tipe terberat dari AIJ. Tatalaksana standar yang diberikan sering tidak memberikan respons klinis optimal sehingga meningkatkan morbiditas dan mortalitas. Pemberian agen biologis seperti tocilizumab atau anakinra merupakan pilihan agen biologis untuk tatalaksana AIJ sistemik.
Tujuan. Mengumpulkan bukti ilmiah tentang efektivitas pemberian tocilizumab dibandingkan anakinra dalam tatalaksana AIJ sitemik.
Metode. Pencarian artikel dilakukan secara daring menggunakan instrumen kata kunci yang sesuai melalui basis data Pubmed, Cochrane dan Google Scholar pada bulan Februari 2022.
Hasil. Penelusuran dilakukan dan didapatkan dua artikel dengan kohort retrospektif. Remisi klinis pada kelompok tocilizumab berkisar sekitar 44-45%, sedangkan pada kelompok anakinra berkisar 25-38%.
Kesimpulan. Tocilizumab memberikan respons klinis yang lebih baik dibandingkan anakinra dalam tatalaksana AIJ sistemik.


Kata Kunci


artritis idiopatik juvenil sistemik; tocilizumab; anakinra

Teks Lengkap:

PDF

Referensi


Thierry S, Fautrel B, Lemelle I, Guillemin F. Prevalence and incidence of juvenile idiopathic arthritis: a systematic review. Joint Bone Spine 2014;81:112-7.

Petty RE, Southwood TR, Manners P. International League of Associations for Rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001. J Rheumatol 2004;31:390-2.

Janow G, Schanberg LE, Setoguchi S, dkk. The Systemic Juvenile Idiopathic Arthritis Cohort of the Childhood Arthritis and Rheumatology Research Alliance Registry: 2010-2013. J Rheumatol 2016;43:1755-62.

Muzaffer MA, Abdelgalil AA. Tocilizumab in the management of refractory juvenile idiopathic artritis, 10 years of experience at tertiary university hospital. Egypt Rheumatol 2021;48:1-7.

Kearsley-Fleet L, Beresford MW, Davies R, dkk. Short-term outcomes in patients with systemic juvenile idiopathic arthritis treated with either tocilizumab or anankinra. Rheumatol 2019;58:94–102.

Horneff G, Schulz AN, Klotsche JK, dkk. Experience with etanercept, tocilizumab, and interleukin-1 inhibitors in systemic onset juvenile idiopathic arthritis patients from the BIKER registry. Arthritis Res Ther 2017;19:256-69.

Nigrovic PA. Is there a window of opportunity for treatment of systemic juvenile idiopathic arthritis?. Arthritis Rheumatol 2014;66:1405-13.

Ogilvie EM, Khan A, Hubank M, Kellam P, Woo P. Specific gene expression profiles in systemic juvenile idiopathic arthritis. Arthritis Rheum 2007;56:1954-65.

Nigrovic PA, Beukelman T, Tomlinson G, Feldman BM, Schanberg L, Kimura Y. Bayesian comparative effectiveness study of four consensus treatment plans for initial management of systemic juvenile idiopathic arthritis: First Line Options for Systemic juvenile idiopathic arthritis Treatment (FROST). Clin Trials 2018;15:268-77.

Sota J, Rigante D, Ruscitti P, dkk. Anakinra drug retention rate and predictive factors of long-term response in systemic juvenile idiopathic arthritis and adult onset still disease. Front Pharmacol 2019;10:1-8.

Lin YT, Wang CT, Gershwin ME, Chiang BL. The pathogenesis of oligoarticular/polyarticular vs systemic juvenile idiopathic arthritis. Autoimmun Rev 2011;10:482-9.

Doeleman MJH, Maarseveen EMV, Swart JF. Immunogenicity of biologic agents in juvenile idiopathic systematic review and meta-analysis. Rheumatol 2019;10:1839-49.

Magni-Manzoni S, Ruperto N, Pistorio A, dkk. Development and validation of preliminary definition of minimal disease activity in patients with juvenile idiopathic arthritis. Arthritis Rheum 2008;59:1120-7.

Grevich S, Shenoi S. Update on the management of systemic juvenile idiopathic arthritis and role of IL-1 and IL-6 inhibition. Adolesc Health Med Ther 2017;8:125-35.

Imagawa T, Yokota S, Mori M, dkk. Safety and efficacy of tocilizumab, an anti-IL-6-receptor monoclonal antibody, in patients with polyarticular-course juvenile idiopathic arthritis. Mod Rheumatol 2012;22:109-15.




DOI: http://dx.doi.org/10.14238/sp24.4.2022.273-8

Refbacks

  • Saat ini tidak ada refbacks.


##submission.copyrightStatement##

##submission.license.cc.by-nc-sa4.footer##

Informasi Editorial:
Badan Penerbit Ikatan Dokter Anak Indonesia
Jl. Salemba I No 5, Jakarta 10430, Indonesia
Phone/Fax: +62-21-3912577
Email: editorial [at] saripediatri.org

Lisensi Creative Commons
Sari Pediatri diterbitkan oleh Badan Penerbit Ikatan Dokter Anak Indonesia
Ciptaan disebarluaskan di bawah Lisensi Creative Commons Atribusi-NonKomersial-BerbagiSerupa 4.0 Internasional.